Literature DB >> 8164839

Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.

Y H Sohn1, L V Metman, D Bravi, I Linfante, A Aotsuka, M M Mouradian, T N Chase.   

Abstract

We measured the time to peak antiparkinson response following injection of levodopa or apomorphine in 57 patients with Parkinson's disease. The peak response time for levodopa fell from 53 +/- 6.5 minutes in patients at Hoehn and Yahr stage I-II, and 28 +/- 4.8 minutes in those at stage IV (p < 0.0005). There was a significant correlation between levodopa peak response time and symptom duration (r = 0.65; p < 0.0001), but there was no relation between apomorphine peak response time and measures of disease severity. Peak response time to levodopa appears to reflect predominantly the status of compensatory presynaptic dopaminergic mechanisms and thus may provide an index to the degree of dopamine neuron degeneration in parkinsonian patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164839     DOI: 10.1212/wnl.44.4.755

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

3.  Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

Authors:  John G Nutt; Kathy A Chung; Nicholas H G Holford
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

Review 4.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

5.  Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease.

Authors:  Kevin J Black; Haley K Acevedo; Jonathan M Koller
Journal:  Front Neurol       Date:  2020-05-06       Impact factor: 4.003

Review 6.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.